|
|
|
Insider
Information: |
Green Jeremy |
Relationship: |
Former 10% Owner and D... |
City: |
San Francisco |
State: |
CA |
|
|
Insider
Summary: |
|
|
|
Companies Owned : |
31 |
|
Direct
Shares |
49,793 |
|
Indirect Shares
|
116,486,068 |
|
|
Direct
Value |
$253,944 |
|
|
Indirect Value
|
$307,215,684 |
|
|
Total
Shares |
116,535,861 |
|
|
Total
Value |
$307,469,628 |
|
|
|
|
|
|
|
|
Historical
Performance :
Based on 6 Month Return Percentages |
Buys
|
Sells
|
Total
Filings :
|
9
|
1
|
Stock
price went up :
|
1
|
0
|
Stock
price went down : |
8
|
1
|
|
|
|
Gain/Loss Ratio : |
0.0
|
-1.0
|
Percentage
Gain/Loss : |
-17.0%
|
-38.6%
|
|
|
|
|
|
|
Holdings
:
Menu |
Company Name |
Ticker |
Relation |
Direct Date |
Direct Shares |
Indirect Date |
Indirect Shares |
Total Value Sold |
|
Amicus Therapeutics Inc |
FOLD |
10% Owner |
2016-06-03 |
0 |
2016-06-03 |
12,956,446 |
Premium* |
|
Syros Pharmaceuticals, Inc. |
SYRS |
10% Owner |
2016-07-06 |
49,793 |
2016-07-06 |
0 |
Premium* |
|
Xeris Pharmaceuticals Inc |
XERS |
10% Owner |
2018-06-25 |
0 |
2019-02-19 |
3,000,642 |
Premium* |
|
Allakos Inc. |
ALLK |
10% Owner |
2018-07-23 |
0 |
2018-07-23 |
1,009,090 |
Premium* |
|
Replimune Group Inc |
REPL |
10% Owner |
2018-07-24 |
0 |
2018-07-24 |
779,655 |
Premium* |
|
Fate Therapeutics Inc |
FATE |
Director, 10% Owner |
2018-09-25 |
0 |
2023-12-26 |
13,180,388 |
Premium* |
|
Gritstone Oncology, Inc. |
GRTS |
10% Owner |
2018-10-02 |
0 |
2018-10-02 |
1,394,529 |
Premium* |
|
Vapotherm Inc |
VAPO |
10% Owner |
2018-11-16 |
0 |
2018-11-16 |
959,540 |
Premium* |
|
Tcr2 Therapeutics Inc. |
TCRR |
10% Owner |
2019-02-19 |
0 |
2019-02-19 |
807,256 |
Premium* |
|
Alder Biopharmaceuticals Inc |
ALDR |
Director |
2019-03-04 |
0 |
2019-10-22 |
0 |
Premium* |
|
Akero Therapeutics, Inc. |
AKRO |
10% Owner |
2019-06-24 |
0 |
2019-06-24 |
743,802 |
Premium* |
|
Atreca Inc |
BCEL |
10% Owner |
2019-06-24 |
0 |
2019-06-24 |
715,306 |
Premium* |
|
Stoke Therapeutics, Inc. |
STOK |
10% Owner |
2019-06-21 |
0 |
2019-06-21 |
671,808 |
Premium* |
|
Igm Biosciences, Inc. |
IGMS |
10% Owner |
2019-09-20 |
0 |
2024-03-29 |
3,078,332 |
Premium* |
|
Aprea Therapeutics, Inc. |
APRE |
10% Owner |
2019-10-07 |
0 |
2020-12-28 |
1,768,718 |
Premium* |
|
Cabaletta Bio, Inc. |
CABA |
10% Owner |
2019-10-29 |
0 |
2019-10-29 |
696,378 |
Premium* |
|
Beam Therapeutics Inc. |
BEAM |
10% Owner |
2020-02-10 |
0 |
2020-02-10 |
1,161,458 |
Premium* |
|
Neurogene |
NGNE |
10% Owner |
2020-03-27 |
0 |
2020-04-02 |
4,041,211 |
Premium* |
|
Pliant Therapeutics, Inc. |
PLRX |
10% Owner |
2020-06-05 |
0 |
2020-06-05 |
1,910,657 |
Premium* |
|
Repare Therapeutics Inc. |
RPTX |
10% Owner |
2020-06-23 |
0 |
2020-06-23 |
1,586,174 |
Premium* |
|
Nurix Therapeutics, Inc. |
NRIX |
10% Owner |
2020-07-28 |
0 |
2020-07-28 |
1,176,470 |
Premium* |
|
Annexon, Inc. |
ANNX |
10% Owner |
2020-07-28 |
0 |
2020-07-28 |
1,596,222 |
Premium* |
|
Allovir Inc |
ALVR |
10% Owner |
2020-08-03 |
0 |
2020-08-03 |
823,371 |
Premium* |
|
Kymera Therapeutics, Inc. |
KYMR |
10% Owner |
2020-08-25 |
0 |
2020-08-25 |
1,630,660 |
Premium* |
|
Augmedix, Inc |
AUGX |
Director, 10% Owner |
2020-10-05 |
0 |
2024-03-15 |
16,408,909 |
Premium* |
|
Shattuck Labs, Inc. |
STTK |
Director, 10% Owner |
2020-10-14 |
0 |
2024-03-28 |
5,615,489 |
Premium* |
|
MedAvail Holdings, Inc |
MDVL |
Director, 10% Owner |
|
0 |
2022-04-04 |
25,192,751 |
Premium* |
|
Verve Therapeutics, Inc. |
VERV |
10% Owner |
2021-06-21 |
0 |
2021-06-21 |
1,936,530 |
Premium* |
|
Absci Corp |
ABSI |
Director |
2021-07-26 |
0 |
2024-03-01 |
8,253,316 |
Premium* |
|
Adagio Therapeutics, Inc. |
ADGI |
10% Owner |
2021-08-10 |
0 |
2021-08-10 |
3,390,960 |
Premium* |
|
Science 37 Holdings, Inc |
SNCE |
Former 10% Owner and D... |
2021-10-06 |
0 |
2024-03-12 |
0 |
Premium* |
|
|
|
|
|
|
|
|
|
|
Records found :
110 |
Free Registration Required For Full Results. Limit: 25
|
|
Download |
Page 2 of 5
|
Ticker |
Company Name |
Relation |
Off-Dir-10% |
Trans. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
3m +/- |
|
|
Form |
NGNE |
Neurogene |
10% Owner |
|
2020-03-31 |
4 |
B |
$10.18 |
$309,389 |
I/I |
30,000 |
3,979,079 |
1.5 |
- |
|
NGNE |
Neurogene |
10% Owner |
|
2020-04-01 |
4 |
B |
$10.95 |
$471,630 |
I/I |
42,500 |
4,021,579 |
1.5 |
- |
|
NGNE |
Neurogene |
10% Owner |
|
2020-04-01 |
4 |
S |
$11.06 |
$108,940 |
I/I |
(9,834) |
4,011,745 |
0 |
- |
|
IGMS |
Igm Biosciences, Inc. |
10% Owner |
|
2020-04-01 |
4 |
A |
$0.00 |
$0 |
I/I |
178 |
3,144,178 |
0 |
- |
|
NGNE |
Neurogene |
10% Owner |
|
2020-04-02 |
4 |
B |
$11.36 |
$446,958 |
I/I |
39,300 |
4,051,045 |
1.5 |
- |
|
NGNE |
Neurogene |
10% Owner |
|
2020-04-02 |
4 |
S |
$11.30 |
$111,214 |
I/I |
(9,834) |
4,041,211 |
0 |
- |
|
PLRX |
Pliant Therapeutics, Inc. |
10% Owner |
|
2020-06-05 |
4 |
A |
$0.00 |
$0 |
I/I |
1,910,657 |
1,910,657 |
0 |
- |
|
FATE |
Fate Therapeutics Inc |
Director |
|
2020-06-11 |
4 |
B |
$28.31 |
$39,999,992 |
I/I |
1,412,928 |
12,629,737 |
2.25 |
% |
|
RPTX |
Repare Therapeutics Inc. |
10% Owner |
|
2020-06-23 |
4 |
A |
$0.00 |
$0 |
I/I |
1,586,174 |
1,586,174 |
0 |
- |
|
IGMS |
Igm Biosciences, Inc. |
10% Owner |
|
2020-07-01 |
4 |
A |
$0.00 |
$0 |
I/I |
178 |
3,144,356 |
0 |
- |
|
NRIX |
Nurix Therapeutics, Inc. |
10% Owner |
|
2020-07-28 |
4 |
A |
$0.00 |
$0 |
I/I |
1,176,470 |
1,176,470 |
0 |
- |
|
ANNX |
Annexon, Inc. |
10% Owner |
|
2020-07-28 |
4 |
A |
$0.00 |
$0 |
I/I |
1,596,222 |
1,596,222 |
0 |
- |
|
ALVR |
Allovir Inc |
10% Owner |
|
2020-08-03 |
4 |
A |
$0.00 |
$0 |
I/I |
823,371 |
823,371 |
0 |
- |
|
KYMR |
Kymera Therapeutics, Inc. |
10% Owner |
|
2020-08-25 |
4 |
A |
$0.00 |
$0 |
I/I |
1,630,660 |
1,630,660 |
0 |
- |
|
IGMS |
Igm Biosciences, Inc. |
Director |
|
2020-09-01 |
4 |
B |
$44.84 |
$1,872,327 |
I/I |
41,759 |
3,186,115 |
2.25 |
- |
|
IGMS |
Igm Biosciences, Inc. |
Director |
|
2020-09-02 |
4 |
B |
$45.54 |
$963,267 |
I/I |
20,637 |
3,206,752 |
2.25 |
- |
|
IGMS |
Igm Biosciences, Inc. |
Director |
|
2020-09-03 |
4 |
B |
$48.69 |
$3,615,208 |
I/I |
74,253 |
3,281,005 |
2.25 |
- |
|
IGMS |
Igm Biosciences, Inc. |
Director |
|
2020-09-04 |
4 |
B |
$50.28 |
$3,742,186 |
I/I |
74,433 |
3,355,438 |
2.25 |
- |
|
IGMS |
Igm Biosciences, Inc. |
Director |
|
2020-09-08 |
4 |
B |
$49.91 |
$2,351,504 |
I/I |
47,113 |
3,402,551 |
2.25 |
- |
|
IGMS |
Igm Biosciences, Inc. |
Director |
|
2020-09-09 |
4 |
B |
$51.85 |
$1,222,335 |
I/I |
23,260 |
3,425,811 |
2.25 |
- |
|
IGMS |
Igm Biosciences, Inc. |
Director |
|
2020-10-01 |
4 |
A |
$0.00 |
$0 |
I/I |
178 |
3,425,989 |
0 |
- |
|
AUGX |
Augmedix, Inc |
Director |
|
2020-10-05 |
4 |
B |
$3.00 |
$15,000,000 |
I/I |
5,000,000 |
12,755,327 |
2.25 |
- |
|
STTK |
Shattuck Labs, Inc. |
Director |
|
2020-10-14 |
4 |
A |
$0.00 |
$0 |
I/I |
2,178,738 |
2,178,738 |
0 |
- |
|
STTK |
Shattuck Labs, Inc. |
Director |
|
2020-10-14 |
4 |
B |
$17.00 |
$59,669,343 |
I/I |
3,441,176 |
5,619,914 |
2.25 |
- |
|
APRE |
Aprea Therapeutics, Inc. |
10% Owner |
|
2020-12-28 |
4 |
S |
$5.58 |
$2,791,290 |
I/I |
(500,000) |
1,768,718 |
0 |
- |
|
110 Records found
|
|
Page 2 of 5 |
|
Free Registration Required For Full Results. Limit: 25
|
|
|
Transaction Code Key: |
Ownership Code Key |
|
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
|
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
|
OE |
- Options Exercised |
A |
- Aquired |
|
IO |
- Initital Ownership |
D |
- Disposed |
|
|
|
|
|
|